PubRank

Joe Y Chang

Author PubWeight™ 104.04‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013 4.72
2 Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol 2005 4.00
3 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 2007 2.80
4 Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012 2.17
5 Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2009 2.08
6 Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006 2.04
7 Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat Oncol Biol Phys 2013 2.01
8 Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004 1.94
9 Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010 1.90
10 Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 2007 1.74
11 Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 1.68
12 Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012 1.61
13 Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 2010 1.58
14 Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys 2008 1.56
15 Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005 1.53
16 Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL. Eur J Nucl Med Mol Imaging 2006 1.53
17 Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 2006 1.52
18 The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg 2012 1.51
19 Cardiac ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 2013 1.44
20 Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiat Oncol 2009 1.36
21 Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012 1.34
22 Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010 1.30
23 Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007 1.28
24 Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011 1.27
25 Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys 2012 1.20
26 Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 2008 1.18
27 Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 2009 1.17
28 Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2007 1.13
29 Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 2010 1.12
30 Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 2011 1.12
31 Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 2006 1.11
32 The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 2006 1.07
33 Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer 2013 1.07
34 Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012 1.05
35 Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. Cancers (Basel) 2011 1.04
36 Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Res 2014 1.04
37 Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008 1.03
38 A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 2005 0.99
39 Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys 2009 0.99
40 Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 2007 0.98
41 Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy? Int J Radiat Oncol Biol Phys 2012 0.98
42 Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011 0.97
43 Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005 0.97
44 Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? Thorac Surg Clin 2013 0.96
45 Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res 2013 0.96
46 Evaluation of tumor position and PTV margins using image guidance and respiratory gating. Int J Radiat Oncol Biol Phys 2010 0.95
47 Adaptive radiation for lung cancer. J Oncol 2010 0.95
48 Implementation of feedback-guided voluntary breath-hold gating for cone beam CT-based stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2011 0.93
49 Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 2014 0.93
50 Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 2007 0.93
51 Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013 0.92
52 Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 2013 0.92
53 Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol 2013 0.92
54 The expression of HIF-1α in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep 2011 0.92
55 Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol 2006 0.92
56 Assessment of lung tumor motion and setup uncertainties using implanted fiducials. Int J Radiat Oncol Biol Phys 2007 0.91
57 Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004 0.89
58 Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res 2005 0.89
59 Comparison of efficacy of regional and extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007 0.88
60 Daily alignment results of in-room computed tomography-guided stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2010 0.87
61 A prospective evaluation of staging and target volume definition of lymph nodes by 18FDG PET/CT in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 2011 0.87
62 Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 2004 0.86
63 Clinical controversies: proton therapy for thoracic tumors. Semin Radiat Oncol 2013 0.86
64 Oligometastases/Oligo-recurrence of lung cancer. Pulm Med 2013 0.85
65 Esophageal cancer: diagnosis and management. Chin J Cancer 2010 0.84
66 Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer 2009 0.83
67 Cine computed tomography without respiratory surrogate in planning stereotactic radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008 0.83
68 Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol 2013 0.83
69 Telomerase: a potential molecular marker and therapeutic target for cancer. J Surg Oncol 2004 0.82
70 GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer. Radiother Oncol 2009 0.82
71 Erratum. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 2016 0.82
72 Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg 2010 0.81
73 New weighted maximum-intensity-projection images from cine CT for delineation of the lung tumor plus motion. Med Phys 2013 0.81
74 Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 2007 0.81
75 Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep 2008 0.81
76 Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother Oncol 2012 0.80
77 Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim 2013 0.80
78 The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume. Int J Radiat Oncol Biol Phys 2006 0.79
79 Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol 2011 0.79
80 Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol 2014 0.78
81 Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med 2012 0.78
82 Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep 2007 0.78
83 FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol 2012 0.77
84 A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. J Appl Clin Med Phys 2008 0.77
85 Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex. Anticancer Drugs 2004 0.77
86 Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 2014 0.77
87 Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J 2016 0.76
88 Knocking Down Nucleolin Expression Enhances the Radiosensitivity of Non-Small Cell Lung Cancer by Influencing DNA-PKcs Activity. Asian Pac J Cancer Prev 2015 0.76
89 Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J 2016 0.75
90 Proton therapy in clinical practice. Chin J Cancer 2011 0.75
91 Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. Cancers (Basel) 2011 0.75
92 Improved longitudinal length accuracy of gross tumor volume delineation with diffusion weighted magnetic resonance imaging for esophageal squamous cell carcinoma. Radiat Oncol 2013 0.75
93 Outcomes with esophageal cancer radiation therapy. J Thorac Oncol 2009 0.75
94 Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 2009 0.75
95 Oncology scan--promising strategies for the treatment of locally-advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013 0.75
96 Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol 2005 0.75